Each drop of blood carries billions of messages with critical information.
This wealth of information is transmitted throughout our bodies via the bloodstream using a complex extracellular vesicle messaging system.
It is a monumental challenge to detect and decipher these messages to better diagnose and manage the treatment of disease.
Our core technology can read and decipher information from millions of particles in a single drop of blood with unprecedented accuracy.
Our non-invasive and cost-effective technology combines advanced microflow cytometry with sophisticated machine learning algorithms and is currently in developmental trials to provide more timely and accurate information that can be used to better understand disease.
Nanostics announces plans to use the ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida.
“We’re joining the fight against COVID-19 by using our ClarityDX technology to rapidly and accurately predict which COVID-19 patients are at risk for developing severe disease,” said John Lewis, CEO of Nanostics.
Our bodies use tiny messengers, called extracellular vesicles, to communicate throughout the body. At Nanostics we are developing a novel technology that deciphers these messages to diagnose disease better–we are creating a new test that more accurately diagnoses clinically significant prostate cancer from a few drops of blood.